- 专利标题： PYRAZOLE-AMIDE COMPOUND AND MEDICINAL USES THEREFOR
-
申请号： EP20204677.7申请日： 2014-03-14
-
公开(公告)号： EP3805205A1公开(公告)日： 2021-04-14
- 发明人: MOTOMURA, Takahisa , SHOMI, Gakujun
- 申请人： Japan Tobacco Inc.
- 申请人地址： JP Tokyo 105-6927 1-1, Toranomon 4-chome Minato-ku
- 代理机构： Vossius & Partner Patentanwälte Rechtsanwälte mbB
- 优先权： JP2013127318 20130618
- 主分类号： C07D231/12
- IPC分类号： C07D231/12 ; A61K31/415 ; A61P3/00 ; A61P3/04 ; A61P3/10 ; A61P9/04 ; A61P9/10 ; A61P11/00 ; A61P13/12 ; A61P25/00 ; A61P27/02 ; A61P27/12 ; A61P43/00
摘要：
The present invention relates to a combination drug comprising (a) compound represented by the formula [I]:
wherein n is 1 or 2, or a pharmaceutically acceptable salt thereof; and
(b) at least one other medicament effective for the prophylaxis or treatment of a disease selected from the group consisting of diabetes such as (i) type 1 diabetes or (ii) type 2 diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications such as (i) diabetic neuropathy, (ii) diabetic retinopathy, (iii) diabetic nephropathy or (iii) cataract, cardiac failure such as (i)acute cardiac failure or (ii) chronic cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension and Alzheimer disease, wherein the medicament (b) is/are administered simultaneously, separately or continuously.
wherein n is 1 or 2, or a pharmaceutically acceptable salt thereof; and
(b) at least one other medicament effective for the prophylaxis or treatment of a disease selected from the group consisting of diabetes such as (i) type 1 diabetes or (ii) type 2 diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications such as (i) diabetic neuropathy, (ii) diabetic retinopathy, (iii) diabetic nephropathy or (iii) cataract, cardiac failure such as (i)acute cardiac failure or (ii) chronic cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension and Alzheimer disease, wherein the medicament (b) is/are administered simultaneously, separately or continuously.
信息查询
